Mainz, Germany, 16th December 2015: BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, today announced that Sean Marett, COO of BioNTech, will be presenting an overview of the company at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday 12th January 2016 at 04:00 pm Pacific Standard Time. The event will be held at the Westin St. Francis Hotel in San Francisco.
Furthermore, the company’s management team, Prof. Dr. Ugur Sahin, CEO, Sean Marett, COO, and Dr. Sierk Poetting, CFO will all be attending the J.P. Morgan Healthcare Conference.
The J.P. Morgan Healthcare Conference brings together corporate leaders, financial sponsors and institutional investors to explore market and sector trends. The 34th Annual J.P. Morgan Healthcare Conference will be held on 11th – 14th January 2016 in San Francisco.
For further information, please contact:
BioNTech AG
Regina Jehle
Tel: +49 (0) 6131 9084 1273
Email: Regina.Jehle@biontech.de
Hume Brophy
Mary Clark, Eva Haas, Hollie Vile
Tel: +44 (0) 20 3440 5813
Email: biontech@humebrophy.com
Notes to editors
About BioNTech AG
BioNTech AG is an immunotherapy leader with bench-to-market capabilities, developing truly personalized, well-tolerated & potent treatments for cancer and other diseases. Established by clinicians and scientists, the Group is pioneering disruptive technologies ranging from individualized mRNA based medicines through innovative Chimeric Antigen Receptors /T-cell Receptor-based products and novel antibody checkpoint immunomodulators. BioNTech’s clinical programs are supported by an in-house molecular diagnostics unit whose products include MammaTyper®, a molecular in-vitro diagnostic kit marketed under CE and IVD marking in Europe and certain other countries. Founded in 2008, BioNTech is privately held, with the Strüngmann Family Office as a majority shareholder. Information about BioNTech is available at www.biontech.de.
Furthermore, the company’s management team, Prof. Dr. Ugur Sahin, CEO, Sean Marett, COO, and Dr. Sierk Poetting, CFO will all be attending the J.P. Morgan Healthcare Conference.
The J.P. Morgan Healthcare Conference brings together corporate leaders, financial sponsors and institutional investors to explore market and sector trends. The 34th Annual J.P. Morgan Healthcare Conference will be held on 11th – 14th January 2016 in San Francisco.
For further information, please contact:
BioNTech AG
Regina Jehle
Tel: +49 (0) 6131 9084 1273
Email: Regina.Jehle@biontech.de
Hume Brophy
Mary Clark, Eva Haas, Hollie Vile
Tel: +44 (0) 20 3440 5813
Email: biontech@humebrophy.com
Notes to editors
About BioNTech AG
BioNTech AG is an immunotherapy leader with bench-to-market capabilities, developing truly personalized, well-tolerated & potent treatments for cancer and other diseases. Established by clinicians and scientists, the Group is pioneering disruptive technologies ranging from individualized mRNA based medicines through innovative Chimeric Antigen Receptors /T-cell Receptor-based products and novel antibody checkpoint immunomodulators. BioNTech’s clinical programs are supported by an in-house molecular diagnostics unit whose products include MammaTyper®, a molecular in-vitro diagnostic kit marketed under CE and IVD marking in Europe and certain other countries. Founded in 2008, BioNTech is privately held, with the Strüngmann Family Office as a majority shareholder. Information about BioNTech is available at www.biontech.de.
